arrow
D

David M. Gershenson

The University of Texas MD Anderson Cancer Center
H指数:99
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PPP2R1A mutations portend improved survival after cancer immunotherapy

PPP2R1A突变预示癌症免疫治疗后生存率提高

Nature
IF48.5
2025-07-020
OA
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment

重新利用美国食品药品监督管理局批准的癌症疗法:探索低级别浆液性卵巢癌治疗中的内分泌和靶向通路

2025-05-150
PRE
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301:一项评估阿伏莫替尼联合达法他尼与研究者选择治疗方案相比,在复发性低级别浆液性卵巢癌患者中的随机III期试验

2025-04-190
OAAI
Ovarian Cancer/Fallopian Tube Cancer/Primary PeritonealCancer, Version 3.2024Featured Updates to the NCCN Guidelines

卵巢癌/输卵管癌/原发性腹膜癌,版本3.2024 NCCN指南重点更新

2024-10-0115
PRE
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors

复发成人型卵巢颗粒细胞瘤的连续细胞减灭术和生存结果

2024-05-013
OAAI
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer

tremelimumab和durvalumab联合与序贯治疗复发性铂类耐药卵巢癌的随机2期试验

CANCER
IF5.1
2023-11-274
PRE
First results from the ENGOT-GYN2/ GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) plus bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
2023-10-014
OA
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

从短期和长期幸存者收集的低级别卵巢浆液性癌的综合多组学分析

2022-12-1711
OAAI
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma (vol 12, pg 939, 2006)

慢性应激促进卵巢癌小鼠模型中的肿瘤生长和血管生成 (第12卷,939页,2006)

2021-11-193
OA